[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:cd70-antigen":3},{"name":4,"total":5,"recruiting":6,"trials":7},"CD70 Antigen",12,7,[8,16,22,29,35,41,47,53,60,67,73,79],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05353530","IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma",[12],"Phase 1","RECRUITING","2026-08-26T02:16:39.977107Z","2026-05-29T15:36:40.165825Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT07072234","Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma",[12],"2026-08-26T02:18:13.438956Z","2026-05-05T02:43:27.480320Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT06930651","A Phase I\u002FII Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed\u002FRefractory Myeloid Malignancies",[26],"Phase 1\u002FPhase 2","2026-08-26T02:18:33.598205Z","2026-05-05T02:43:29.673718Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT07444632","Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed\u002FRefractory Lymphoid Malignancies",[12],"2026-08-26T02:16:36.513735Z","2026-05-05T02:43:28.704804Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT05092451","Phase I\u002FII Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse\u002FRefractory Hematological Malignances",[26],"2026-08-26T02:16:55.892527Z","2026-05-05T02:43:27.847376Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT06326463","CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies",[12],"2026-08-26T02:17:33.807405Z","2026-05-05T02:35:31.873958Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT02830724","Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers",[26],"2026-08-26T02:16:42.787115Z","2026-05-05T02:35:31.639158Z",{"nct_id":54,"title":55,"phases":56,"status":57,"updated_at":58,"content_modified":59},"NCT07569263","IL-8 Receptor Modified Patient-Derived Activated CD70 CAR T Cell Therapy in Adults With Brain Metastases",[12],"NOT_YET_RECRUITING","2026-08-26T02:15:43.339060Z","2026-05-13T02:55:06.733711Z",{"nct_id":61,"title":62,"phases":63,"status":57,"updated_at":65,"content_modified":66},"NCT07164469","Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma",[64],"Phase 2","2026-08-26T02:18:19.586423Z","2026-05-05T02:43:29.215963Z",{"nct_id":68,"title":69,"phases":70,"status":57,"updated_at":71,"content_modified":72},"NCT06345027","Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)",[12],"2026-08-26T02:15:31.806698Z","2026-05-05T02:43:27.285966Z",{"nct_id":74,"title":75,"phases":76,"status":57,"updated_at":77,"content_modified":78},"NCT06946680","IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Newly Diagnosed and Recurrent Pediatric High-grade Glioma (pHGG) and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (ndDIPG)",[12],"2026-08-26T02:17:52.450442Z","2026-05-29T15:36:40.176961Z",{"nct_id":80,"title":81,"phases":82,"status":57,"updated_at":83,"content_modified":84},"NCT07297160","CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors",[12],"2026-08-26T02:16:46.951087Z","2026-05-05T02:43:27.644388Z"]